布拉氏酵母菌联合阴道用药治疗复发性外阴阴道假丝酵母菌病的临床疗效及安全性

目的 探讨布拉氏酵母菌联合阴道用药治疗复发性外阴阴道假丝酵母菌病（RVVC）的临床疗效及安全性。方法 将98例RVVC患者随机分为观察组和对照组各49例，两组均给予硝酸咪康唑栓0.2 g/粒联合重组人干扰素α2b栓10万IU/粒，于月经干净3 d后阴道给药，每次1粒，1次/d。观察组联合布拉氏酵母菌0.5 g/次，2次/d，口服。连续用药3个月经周期，比较两组临床疗效、治疗前及治疗后3、6个月阴道分泌物炎性指标水平、复发情况及不良反应等。结果 观察组临床总有效率明显高于对照组（χ2=4.305，P0.05）。治疗后3个月、6个月两组IL-6水平逐渐下降，IFN-γ水平逐渐上升，但观察组升降幅度明显高于对照组（P<0.01）。结论 布拉氏酵母菌联合阴道用药治疗RVVC的临床疗效显著，能有效改善阴道炎症因子水平，安全有效且复发率低。

Clinical efficacy and safety of Saccharomyces boulardii combined with vaginal medication in treatment of recurrent vulvovaginal candidiasis

Objective To explore the clinical efficacy and safety of Saccharomyces boulardii combined with vaginal medication in the treatment of recurrent vulvovaginal candidiasis（RVVC）．Methods 98 patients with RVVC were randomly divided into observation group or control group（n=49 each）．Both groups were given 0.2 g miconazole nitrate suppository combined with 100，000 IU recombinant human interferon α2b suppository 3 days after menstrual cycle ended，1 granule qd vaginally；the observation group was additionally given Saccharomyces boulardii 0.5 g bid orally．After treated for three consecutive menstrual cycles，the clinical efficacy of the two groups，levels of inflammatory markers in vaginal secretions before treatment and 3 and 6 months after treatment，recurrence and adverse reactions were compared between the two groups．Results The total clinical efficiency rate in the observation group was significantly higher than that in the control group（χ2=4.305，P0.05）．At 3 months and 6 months after treatment，the level of IL-6 decreased gradually while that of IFN-γ increased gradually in both groups，with the observation group being significantly superior to the control group（P<0.01）．Conclusion The combination of Saccharomyces boulardii and vaginal medication has remarkable clinical effect for the treatment of RVVC，which can effectively improve the levels of inflammatory factors in vagina．It is safe and effective with low recurrence rate．